Sou Hu Cai Jing·2025-11-17 10:36Core Viewpoint - Yabao Pharmaceutical (SH 600351) announced the transfer of 62% equity in its subsidiary Taiyuan Pharmaceutical to Tongxiang Technology for approximately RMB 87.19 million, aiming to optimize asset structure and improve operational efficiency [1] Group 1: Company Actions - The equity transfer will result in Tongxiang Technology holding 95% of Taiyuan Pharmaceutical, while Yabao will retain 5%, leading to Taiyuan Pharmaceutical being excluded from Yabao's consolidated financial statements [1] - The transaction is part of Yabao's strategy to lower management costs and enhance asset operation efficiency [1] Group 2: Financial Performance - For the year 2024, Yabao Pharmaceutical's revenue composition is as follows: 75.46% from pharmaceutical manufacturing, 21.37% from pharmaceutical wholesale, 1.88% from other trading, and 1.29% from other businesses [1] - As of the report date, Yabao Pharmaceutical's market capitalization stands at RMB 4.8 billion [1]